AstraZeneca PLC (AZN) EV/EBITDA Ratio: 15.19x
Is AstraZeneca PLC’s EV/EBITDA ratio high or low?
AstraZeneca PLC's EV/EBITDA ratio of 15.19x is 26% below its 5-year average of 20.59x, near the low end of its 5-year range (14.17x–35.03x).
As of Friday, June 12, 2026. 7.61% below its 12-month average of 16.44x.
AZN EV/EBITDA Ratio Chart
AZN Average EV/EBITDA Ratio Chart
AZN Current vs Average EV/EBITDA Ratio Chart
AZN EV/EBITDA Ratio Metrics
EV/EBITDA RATIO
15.19x
EV/EBITDA RATIO AVG TTM
16.44x
EV/EBITDA RATIO AVG 3Y
16.93x
EV/EBITDA RATIO AVG 5Y
20.59x
EV/EBITDA RATIO AVG 10Y
18.55x
EV/EBITDA RATIO AVG 15Y
15.53x
EV/EBITDA RATIO AVG 20Y
13.28x
CURRENT VS TTM AVG
-7.61%
CURRENT VS 3Y AVG
-10.25%
CURRENT VS 5Y AVG
-26.22%
CURRENT VS 10Y AVG
-18.09%
CURRENT VS 15Y AVG
-2.22%
CURRENT VS 20Y AVG
+14.42%
AZN Competitors' EV/EBITDA Ratio
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AstraZeneca PLC (AZN) | $282.69B | 15.19x | 16.44x | 16.93x | 20.59x |
| Merck & Co., Inc. (MRK) | $298.29B | 19.82x | 11.18x | 19.68x | 18.02x |
| UnitedHealth Group Incorporated (UNH) | $368.30B | 18.23x | 11.83x | 15.00x | 15.99x |
| Amgen Inc. (AMGN) | $191.09B | 15.28x | 13.70x | 14.35x | 14.05x |
| Thermo Fisher Scientific Inc. (TMO) | $176.77B | 19.47x | 19.75x | 20.47x | 20.32x |
| AbbVie Inc. (ABBV) | $397.12B | 27.32x | 30.39x | 23.53x | 19.98x |
| Gilead Sciences, Inc. (GILD) | $156.28B | 12.93x | 14.17x | 17.98x | 15.96x |
| Abbott Laboratories (ABT) | $156.15B | 17.55x | 18.77x | 19.31x | 18.59x |
| Pfizer Inc. (PFE) | $149.18B | 12.70x | 10.53x | 15.94x | 13.74x |
| Intuitive Surgical, Inc. (ISRG) | $146.23B | 35.57x | 47.39x | 54.43x | 52.40x |
EV/EBITDA vs. its own history
At 15.2, EV/EBITDA is in its normal range, sitting higher than 55% of its 20-year history.
20-year low
3.5
median
14.1
20-year high
35.0
AstraZeneca PLC EV/EBITDA Ratio Formula & Definition
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
AstraZeneca PLC EV/EBITDA Ratio FAQ
- What is the EV/EBITDA ratio for AstraZeneca PLC (AZN)?
- The EV/EBITDA ratio for AZN stock is 15.19x.
- Is AstraZeneca PLC's EV/EBITDA ratio high or low?
- AstraZeneca PLC's EV/EBITDA ratio of 15.19x is 26% below its 5-year average of 20.59x, near the low end of its 5-year range (14.17x–35.03x).
- What is the TTM average EV/EBITDA ratio for AstraZeneca PLC (AZN)?
- The TTM average EV/EBITDA ratio for AZN stock is 16.44x.
- What is the 3Y average EV/EBITDA ratio for AstraZeneca PLC (AZN)?
- The 3Y average EV/EBITDA ratio for AZN stock is 16.93x.
- What is the 5Y average EV/EBITDA ratio for AstraZeneca PLC (AZN)?
- The 5Y average EV/EBITDA ratio for AZN stock is 20.59x.
- What is the 10Y average EV/EBITDA ratio for AstraZeneca PLC (AZN)?
- The 10Y average EV/EBITDA ratio for AZN stock is 18.55x.
- What is the 15Y average EV/EBITDA ratio for AstraZeneca PLC (AZN)?
- The 15Y average EV/EBITDA ratio for AZN stock is 15.53x.
- What is the 20Y average EV/EBITDA ratio for AstraZeneca PLC (AZN)?
- The 20Y average EV/EBITDA ratio for AZN stock is 13.28x.
AstraZeneca PLC EV/EBITDA Ratio History
| DATE | EV/EBITDA RATIO |
|---|---|
| 2026-06-11 | 15.19x |
| 2026-06-10 | 14.94x |
| 2026-06-09 | 15.28x |
| 2026-06-08 | 15.13x |
| 2026-06-05 | 15.47x |
| 2026-06-04 | 15.15x |
| 2026-06-03 | 14.73x |
| 2026-06-02 | 14.82x |
| 2026-06-01 | 14.99x |
| 2026-05-29 | 15.45x |
| 2026-05-28 | 15.42x |
| 2026-05-27 | 15.45x |
| 2026-05-26 | 15.56x |
| 2026-05-22 | 15.55x |
| 2026-05-21 | 15.76x |
| 2026-05-20 | 15.59x |
| 2026-05-19 | 15.37x |
| 2026-05-18 | 15.32x |
| 2026-05-15 | 15.14x |
| 2026-05-14 | 15.39x |
| 2026-05-13 | 15.61x |
| 2026-05-12 | 15.36x |
| 2026-05-11 | 15.16x |
| 2026-05-08 | 15.23x |
| 2026-05-07 | 15.21x |
| 2026-05-06 | 15.39x |
| 2026-05-05 | 15.11x |
| 2026-05-04 | 15.28x |
| 2026-05-01 | 15.38x |
| 2026-04-30 | 15.58x |
| 2026-04-29 | 15.41x |
| 2026-04-28 | 15.92x |
| 2026-04-27 | 15.98x |
| 2026-04-24 | 16.16x |
| 2026-04-23 | 16.36x |
| 2026-04-22 | 16.56x |
| 2026-04-21 | 16.63x |
| 2026-04-20 | 17.02x |
| 2026-04-17 | 17.34x |
| 2026-04-16 | 17.00x |
| 2026-04-15 | 17.06x |
| 2026-04-14 | 17.31x |
| 2026-04-13 | 17.14x |
| 2026-04-10 | 17.28x |
| 2026-04-09 | 17.36x |
| 2026-04-08 | 17.30x |
| 2026-04-07 | 17.03x |
| 2026-04-06 | 17.19x |
| 2026-04-02 | 17.24x |
| 2026-04-01 | 17.02x |
| 2026-03-31 | 16.75x |
| 2026-03-30 | 16.48x |
| 2026-03-27 | 16.05x |
| 2026-03-26 | 15.66x |
| 2026-03-25 | 15.95x |
| 2026-03-24 | 15.84x |
| 2026-03-23 | 15.71x |
| 2026-03-20 | 15.67x |
| 2026-03-19 | 16.09x |
| 2026-03-18 | 16.05x |
| 2026-03-17 | 16.28x |
| 2026-03-16 | 16.34x |
| 2026-03-13 | 16.17x |
| 2026-03-12 | 16.37x |
| 2026-03-11 | 16.44x |
| 2026-03-10 | 16.57x |
| 2026-03-09 | 16.57x |
| 2026-03-06 | 16.51x |
| 2026-03-05 | 16.77x |
| 2026-03-04 | 17.09x |
| 2026-03-03 | 17.10x |
| 2026-03-02 | 17.26x |
| 2026-02-27 | 17.63x |
| 2026-02-26 | 17.28x |
| 2026-02-25 | 17.42x |
| 2026-02-24 | 17.49x |
| 2026-02-23 | 19.11x |
| 2026-02-20 | 19.04x |
| 2026-02-19 | 19.43x |
| 2026-02-18 | 19.43x |
| 2026-02-17 | 19.50x |
| 2026-02-13 | 19.16x |
| 2026-02-12 | 19.07x |
| 2026-02-11 | 19.09x |
| 2026-02-10 | 18.08x |
| 2026-02-09 | 17.64x |
| 2026-02-06 | 18.08x |
| 2026-02-05 | 17.57x |
| 2026-02-04 | 17.59x |
| 2026-02-03 | 17.32x |
| 2026-02-02 | 17.68x |
| 2026-01-30 | 17.56x |
| 2026-01-29 | 17.22x |
| 2026-01-28 | 17.62x |
| 2026-01-27 | 17.65x |
| 2026-01-26 | 16.87x |
| 2026-01-23 | 16.73x |
| 2026-01-22 | 16.90x |
| 2026-01-21 | 16.51x |
| 2026-01-20 | 17.22x |
| 2026-01-16 | 17.91x |
| 2026-01-15 | 17.71x |
| 2026-01-14 | 17.83x |
| 2026-01-13 | 17.70x |
| 2026-01-12 | 17.42x |
| 2026-01-09 | 17.90x |
| 2026-01-08 | 17.68x |
| 2026-01-07 | 17.88x |
| 2026-01-06 | 17.86x |
| 2026-01-05 | 16.87x |
| 2026-01-02 | 17.18x |
| 2025-12-31 | 16.56x |
| 2025-12-30 | 17.02x |
| 2025-12-29 | 17.56x |
| 2025-12-26 | 17.06x |
| 2025-12-24 | 17.50x |
| 2025-12-23 | 17.21x |
| 2025-12-22 | 17.01x |
| 2025-12-19 | 17.05x |
| 2025-12-18 | 16.99x |
| 2025-12-17 | 17.36x |
| 2025-12-16 | 17.18x |
| 2025-12-15 | 17.28x |
| 2025-12-12 | 16.92x |
| 2025-12-11 | 17.00x |
| 2025-12-10 | 17.11x |
| 2025-12-09 | 16.87x |
| 2025-12-08 | 17.03x |
| 2025-12-05 | 16.90x |
| 2025-12-04 | 16.95x |
| 2025-12-03 | 17.23x |
| 2025-12-02 | 16.87x |
| 2025-12-01 | 16.98x |
| 2025-11-28 | 17.27x |
| 2025-11-26 | 17.68x |
| 2025-11-25 | 17.62x |
| 2025-11-24 | 17.18x |
| 2025-11-21 | 17.17x |
| 2025-11-20 | 16.76x |
| 2025-11-19 | 16.93x |
| 2025-11-18 | 16.53x |
| 2025-11-17 | 16.54x |
| 2025-11-14 | 16.50x |
| 2025-11-13 | 16.73x |
| 2025-11-12 | 16.57x |
| 2025-11-11 | 16.53x |
| 2025-11-10 | 16.51x |
| 2025-11-07 | 15.75x |
| 2025-11-06 | 16.00x |
| 2025-11-05 | 16.50x |
| 2025-11-04 | 16.77x |
| 2025-11-03 | 16.46x |
| 2025-10-31 | 16.73x |
| 2025-10-30 | 16.72x |
| 2025-10-29 | 16.62x |
| 2025-10-28 | 16.80x |
| 2025-10-27 | 16.65x |
| 2025-10-24 | 16.63x |
| 2025-10-23 | 17.04x |
| 2025-10-22 | 16.92x |
| 2025-10-21 | 17.05x |
| 2025-10-20 | 16.93x |
| 2025-10-17 | 17.29x |
| 2025-10-16 | 17.13x |
| 2025-10-15 | 17.03x |
| 2025-10-14 | 17.12x |
| 2025-10-13 | 17.12x |
| 2025-10-10 | 17.15x |
| 2025-10-09 | 17.19x |
| 2025-10-08 | 17.40x |
| 2025-10-07 | 17.21x |
| 2025-10-06 | 17.42x |
| 2025-10-03 | 17.25x |
| 2025-10-02 | 16.72x |
| 2025-10-01 | 16.52x |
| 2025-09-30 | 15.32x |
| 2025-09-29 | 15.00x |
| 2025-09-26 | 15.01x |
| 2025-09-25 | 15.34x |
| 2025-09-24 | 15.27x |
| 2025-09-23 | 15.43x |
| 2025-09-22 | 15.99x |
| 2025-09-19 | 15.77x |
| 2025-09-18 | 15.67x |
| 2025-09-17 | 15.92x |
| 2025-09-16 | 15.64x |
| 2025-09-15 | 15.78x |
| 2025-09-12 | 16.24x |
| 2025-09-11 | 16.47x |
| 2025-09-10 | 16.30x |
| 2025-09-09 | 16.33x |
| 2025-09-08 | 16.57x |
| 2025-09-05 | 16.70x |
| 2025-09-04 | 16.47x |
| 2025-09-03 | 16.49x |
| 2025-09-02 | 16.35x |
| 2025-08-29 | 16.39x |
| 2025-08-28 | 16.12x |
| 2025-08-27 | 16.34x |
| 2025-08-26 | 16.31x |
| 2025-08-25 | 16.56x |
| 2025-08-22 | 16.02x |
| 2025-08-21 | 16.37x |
| 2025-08-20 | 16.08x |
| 2025-08-19 | 16.20x |
| 2025-08-18 | 16.33x |
| 2025-08-15 | 15.87x |
| 2025-08-14 | 15.89x |
| 2025-08-13 | 15.76x |
| 2025-08-12 | 15.20x |
| 2025-08-11 | 15.00x |
| 2025-08-08 | 14.60x |
| 2025-08-07 | 15.11x |
| 2025-08-06 | 15.24x |
| 2025-08-05 | 15.39x |
| 2025-08-04 | 15.39x |
| 2025-08-01 | 15.13x |
| 2025-07-31 | 15.12x |
| 2025-07-30 | 15.88x |
| 2025-07-29 | 15.41x |
| 2025-07-28 | 15.65x |
| 2025-07-25 | 15.77x |
| 2025-07-24 | 15.92x |
| 2025-07-23 | 15.96x |
| 2025-07-22 | 15.44x |
| 2025-07-21 | 15.22x |
| 2025-07-18 | 15.02x |
| 2025-07-17 | 15.11x |
| 2025-07-16 | 15.45x |
| 2025-07-15 | 15.29x |
| 2025-07-14 | 15.56x |
| 2025-07-11 | 15.28x |
| 2025-07-10 | 15.60x |
| 2025-07-09 | 15.39x |
| 2025-07-08 | 15.27x |
| 2025-07-07 | 15.51x |
| 2025-07-03 | 15.32x |
| 2025-07-02 | 15.63x |
| 2025-07-01 | 15.22x |
| 2025-06-30 | 15.23x |
| 2025-06-27 | 15.08x |
| 2025-06-26 | 15.25x |
| 2025-06-25 | 15.85x |
| 2025-06-24 | 15.36x |
| 2025-06-23 | 15.45x |
| 2025-06-20 | 15.22x |
| 2025-06-18 | 15.60x |
| 2025-06-17 | 15.35x |
| 2025-06-16 | 16.06x |
| 2025-06-13 | 16.03x |
| 2025-06-12 | 16.23x |
| 2025-06-11 | 16.05x |
| 2025-06-10 | 15.90x |
| 2025-06-09 | 15.89x |
| 2025-06-06 | 15.67x |
| 2025-06-05 | 15.52x |
| 2025-06-04 | 15.80x |
| 2025-06-03 | 15.49x |
| 2025-06-02 | 15.50x |
| 2025-05-30 | 15.40x |
Showing the most recent 260 of 5,032 data points. The chart above shows the full history.
Related Metrics
About AstraZeneca PLC
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Pascal Claude Roland Soriot